Source link : https://www.newshealth.biz/health-news/inebilizumab-for-myasthenia-gravis-reduces-steroid-burden/
Data from the randomized MINT trial, presented at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) annual meeting, showed that the anti-CD19 monoclonal antibody inebilizumab (Uplizna) for generalized myasthenia gravis improved disease severity, reduced steroid burden, and had a good safety profile. In this exclusive MedPage Today video, Richard Nowak, MD, of the Yale […]
Author : News Health
Publish date : 2024-11-06 19:03:48
Copyright for syndicated content belongs to the linked Source.